GEMLIEVA 200MG ( Gemcitabine for Injection IP 200mg )

GEMLIEVA 200 mg contains Gemcitabine, a pyrimidine nucleoside analogue antimetabolite chemotherapy drug. Inside the cell, it is phosphorylated to active metabolites that inhibit DNA synthesis and induce apoptosis of rapidly dividing cancer cells.

Gemcitabine is used in the treatment of:

1. Pancreatic Cancer

2. Non-Small Cell Lung Cancer (NSCLC)
    – Alone or in combination with cisplatin

3. Breast Cancer
    – Metastatic or refractory disease

4. Ovarian Cancer
     – Platinum-resistant disease

5. Bladder Cancer

Common side effects:

•  Myelosuppression (neutropenia, thrombocytopenia, anemia)

•  Nausea and vomiting

•  Fatigue

•  Fever, flu-like symptoms

Other side effects:

•  Elevated liver enzymes

•  Rash

Serious side effects:

•  Pulmonary toxicity (rare)

•  Hemolytic uremic syndrome (very rare)

CBC, renal and liver function monitoring is required.

Dosage is based on body surface area (BSA) and treatment protocol.

Common dosing schedules:

•  1000–1250 mg/m² IV

•  Given on Days 1, 8, and 15 of a 28-day cycle
    or Days 1 and 8 of a 21-day cycle

200 mg vials are used for dose calculation and adjustment.


NOTE: This medicine should be taken only under a doctor’s supervision.